Phase 3 Clinical Trials With Primary Completion Dates in January 2020

This is a list of Phase 3 trials with primary completion dates in January 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AKBA Akebia Therapeutics, Inc. 2020-01-01 Phase 3 NCT02892149 Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
AKTX Akari Therapeutics, Plc 2020-01-01 Phase 3 NCT03588026 Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576
AMAG AMAG Pharmaceuticals, Inc. 2020-01-01 Phase 3 NCT03297216 Improving Pregnancy Outcomes With Progesterone
BBI Brickell Biotech, Inc. 2020-01-01 Phase 3 NCT03627468 A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
BLUE bluebird bio, Inc. 2020-01-01 Phase 3 NCT02906202 A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype
FLXN Flexion Therapeutics, Inc. 2020-01-01 Phase 3 NCT03529942 Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee
HESG Health Sciences Group, Inc. 2020-01-01 Phase 3 NCT03444324 Adjusted Fibrinogen Replacement Strategy
IRWD Ironwood Pharmaceuticals, Inc. 2020-01-01 Phase 3 NCT03561883 Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors
IRWD Ironwood Pharmaceuticals, Inc. 2020-01-01 Phase 3 NCT03561090 A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors
MNLO Menlo Therapeutics Inc. 2020-01-01 Phase 3 NCT03677401 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
PGNX Progenics Pharmaceuticals, Inc. 2020-01-01 Phase 3 NCT03739684 Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
PRAH PRA Health Sciences, Inc. 2020-01-01 Phase 3 NCT03444324 Adjusted Fibrinogen Replacement Strategy
PRGO Perrigo Company plc 2020-01-01 Phase 3 NCT04024072 To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
SPPI Spectrum Pharmaceuticals, Inc. 2020-01-01 Phase 3 NCT03224182 A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Patients Undergoing TURBT
SPPI Spectrum Pharmaceuticals, Inc. 2020-01-01 Phase 3 NCT01478542 OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine
ZGNX Zogenix, Inc. 2020-01-01 Phase 3 NCT03299842 A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome
ZGNX Zogenix, Inc. 2020-01-01 Phase 3 NCT02826863 A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome